-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech reports new preclinical data for tri-specific antibody IM1240 in resistant tumors

PUBT·04/27/2026 11:01:54
Listen to the news
Purple Biotech reports new preclinical data for tri-specific antibody IM1240 in resistant tumors
  • Purple Biotech disclosed new preclinical data on IM1240, lead tri-specific antibody in its CAPTN-3 platform, on April 27, 2026.
  • Results were presented as newly generated laboratory findings, with no future presentation date specified.
  • IM1240 produced anti-tumor activity across all seven tested patient-derived tumor samples, including treatment-resistant cancers.
  • Data indicated NKG2A targeting contributed materially to the drug’s effect, supporting a potentially improved safety-efficacy balance versus comparable T-cell engagers.
  • Purple Biotech positioned IM1240 as advancing toward clinical testing, with IM1305 remaining in preclinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270700PRIMZONEFULLFEED9707364) on April 27, 2026, and is solely responsible for the information contained therein.